A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/21 (2006.01) A61P 31/14 (2006.01)
Patent
CA 2487299
The use of recombinant IFN-beta for the production of a medicament for the treatment of HCV infection by subcutaneous administration to patients of Asian race, which failed to respond to a previous treatment with interferon -alpha, is herein reported. According to a preferred embodiment of the invention, this treatment can be better and further focused to those patients, which after 4 weeks of initial treatment with IFN-beta show HCV RNA clearance.
La présente invention concerne l'utilisation d'interféron bêta de recombinaison pour produire un médicament destiné à traiter l'infection due au VHC par administration sous-cutanée aux patients de race asiatique n'ayant pas répondu à un traitement précédent à l'interféron alpha. Selon un mode de réalisation préféré de la présente invention, ce traitement peut être mieux concentré, et de manière plus ciblée, sur les patients qui présentent une élimination de l'ARN-VHC après un traitement initial de quatre semaines.
Maschek Birgit
Parsons Ian
Wee Tit Gin Theodor
Applied Research Systems Ars Holding N.v.
Borden Ladner Gervais Llp
Laboratoires Serono S.a.
LandOfFree
Treatment of hepatitis c in the asian population with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of hepatitis c in the asian population with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hepatitis c in the asian population with... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1714028